Bioretec Welcomes Sarah van Hellenberg Hubar-Fisher as New CEO to Drive Growth in Orthopedic Innovations
Bioretec Ltd., renowned for its innovation in absorbable orthopedic implants, proudly announces the appointment of Sarah van Hellenberg Hubar-Fisher as its Chief Executive Officer (CEO), effective immediately. Sarah, who has been serving as the interim CEO since May 2025 and a member of the Board since 2021, steps up to lead the company in accelerating its market presence and optimizing its product offerings. With a solid background in healthcare and medtech, she brings over 23 years of diverse business leadership experience to the role.
Under her guidance, Bioretec aims to bolster its commercial footprint and launch its advanced technologies globally. The announcement follows several regulatory achievements that have put Bioretec on the path to expanding its innovative orthopedic solutions. Sarah will relinquish her positions on the Board of Directors, including the role of Vice Chairperson, to focus solely on her CEO responsibilities. The Board has appointed Antti Vasara as the new Vice Chairman, solidifying a leadership team focused on strategic growth.
"Sarah's rich experience in healthcare management and her successful track record in introducing new technologies globally makes her the perfect fit to lead our company towards its ambitious goal of becoming a leader in absorbable orthopedic implants," stated Kustaa Poutiainen, Chairperson of the Board of Directors. Sarah echoed this enthusiasm, revealing her ambitions for the company, stating, "Our priorities are to accelerate the launch of our promising product RemeOs™, leverage the continuing success of our Activa® line, and ensure we are fully equipped with the resources necessary for substantial scaling."
Bioretec is recognized in approximately 40 countries for its unique solutions that enhance patient outcomes through biodegradable technologies. The Activa® line features fully bioabsorbable implants crafted from a proprietary PLGA polymer, innovatively designed to ensure secure fixation while naturally degrading within two years. This eliminates the need for potentially risky removal surgeries and significantly enhances recovery by promoting optimal bone regeneration.
The recent RemeOs™ line represents a leap forward in orthopedic care, utilizing advanced magnesium alloy and hybrid composite technology. These innovative implants not only facilitate fracture healing but also absorb into the bone, thereby eliminating the need for removal procedures. RemeOs received its CE mark approval in January 2025 and its inaugural market authorization in the U.S. in March 2023, setting Bioretec up for strong future growth.
Sarah's dynamic career includes senior positions at prominent organizations like Johnson & Johnson and roles as a Venture Partner at Spain's Nina Capital and Growth Science Ventures in the U.S. Her academic credentials include an MBA in Entrepreneurship from Babson College and a postgraduate qualification in Global Business from the University of Oxford. Besides leading Bioretec, Sarah contributes to the Board of Global Surgical Initiatives, advocating for sustainability in surgical care for underserved populations.
With her leadership, Bioretec is positioned to refine its market presence and strive towards making a significant clinical impact, thereby enhancing value for shareholders and patients alike. As Sarah leads Bioretec into this exciting chapter, the company's commitment to innovation and patient-centred solutions remains paramount, aiming to redefine standards in orthopedic treatment worldwide.
For more updates, visit Bioretec's official site.
Under her guidance, Bioretec aims to bolster its commercial footprint and launch its advanced technologies globally. The announcement follows several regulatory achievements that have put Bioretec on the path to expanding its innovative orthopedic solutions. Sarah will relinquish her positions on the Board of Directors, including the role of Vice Chairperson, to focus solely on her CEO responsibilities. The Board has appointed Antti Vasara as the new Vice Chairman, solidifying a leadership team focused on strategic growth.
"Sarah's rich experience in healthcare management and her successful track record in introducing new technologies globally makes her the perfect fit to lead our company towards its ambitious goal of becoming a leader in absorbable orthopedic implants," stated Kustaa Poutiainen, Chairperson of the Board of Directors. Sarah echoed this enthusiasm, revealing her ambitions for the company, stating, "Our priorities are to accelerate the launch of our promising product RemeOs™, leverage the continuing success of our Activa® line, and ensure we are fully equipped with the resources necessary for substantial scaling."
Bioretec is recognized in approximately 40 countries for its unique solutions that enhance patient outcomes through biodegradable technologies. The Activa® line features fully bioabsorbable implants crafted from a proprietary PLGA polymer, innovatively designed to ensure secure fixation while naturally degrading within two years. This eliminates the need for potentially risky removal surgeries and significantly enhances recovery by promoting optimal bone regeneration.
The recent RemeOs™ line represents a leap forward in orthopedic care, utilizing advanced magnesium alloy and hybrid composite technology. These innovative implants not only facilitate fracture healing but also absorb into the bone, thereby eliminating the need for removal procedures. RemeOs received its CE mark approval in January 2025 and its inaugural market authorization in the U.S. in March 2023, setting Bioretec up for strong future growth.
Sarah's dynamic career includes senior positions at prominent organizations like Johnson & Johnson and roles as a Venture Partner at Spain's Nina Capital and Growth Science Ventures in the U.S. Her academic credentials include an MBA in Entrepreneurship from Babson College and a postgraduate qualification in Global Business from the University of Oxford. Besides leading Bioretec, Sarah contributes to the Board of Global Surgical Initiatives, advocating for sustainability in surgical care for underserved populations.
With her leadership, Bioretec is positioned to refine its market presence and strive towards making a significant clinical impact, thereby enhancing value for shareholders and patients alike. As Sarah leads Bioretec into this exciting chapter, the company's commitment to innovation and patient-centred solutions remains paramount, aiming to redefine standards in orthopedic treatment worldwide.
For more updates, visit Bioretec's official site.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.